SBFM · XBRL financial data
Sunshine Biopharma financial statements, every fiscal year
The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (SBFM's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | †Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | †Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Revenue | 71 | 228 | 4,346 | 24,093 | 34,874 | 36,306 |
| Cost of revenue | 26 | 118 | 2,649 | 15,754 | 24,204 | 24,050 |
| Gross profit | 46 | 111 | 1,697 | 8,339 | 10,670 | 12,256 |
| Research and development | 61 | 672 | 812 | 1,856 | 934 | 604 |
| General and administrative | 622 | 2,551 | 28,697 | 13,124 | 16,482 | 18,483 |
| Operating income (loss) | (577) | (2,440) | (27,001) | (4,785) | (5,812) | (6,227) |
| Interest expense | 168 | 329 | 39 | 137 | 9 | 0 |
| Income tax expense (benefit) | 0 | 0 | 233 | 395 | (235) | 22 |
| Net income (loss) | (2,784) | (12,436) | (26,744) | (4,506) | (5,134) | (5,975) |
| Earnings per share, basic USD per share | (0.01) | (4.76) | (1.76) | (0.19) | (7.32) | (1.44) |
| Earnings per share, diluted USD per share | — | (4.76) | (1.76) | (0.19) | (7.32) | — |
| Weighted average shares, basic thousands of shares | 204,096 | 2,612 | 15,181 | 24,332 | 702 | 4,157 |
| Weighted average shares, diluted thousands of shares | — | 2,612 | 15,181 | 24,332 | 702 | — |
- † Share count changed about 1/65 in the period ending 2021-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 1/37 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (SBFM's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | †Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | †Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 990 | 2,045 | 21,826 | 16,292 | 9,687 | 9,123 |
| Accounts receivable | 2 | 8 | 1,912 | 2,552 | 3,868 | 3,460 |
| Inventory | 24 | 106 | 3,290 | 5,735 | 11,278 | 13,472 |
| Prepaid and other current assets | 3 | — | — | — | — | — |
| Total current assets | 1,026 | 2,196 | 27,312 | 24,890 | 25,966 | 26,854 |
| Property and equipment, net | 20 | 7 | 394 | 366 | 546 | 557 |
| Right-of-use asset | — | 0 | 760 | 647 | 936 | 779 |
| Goodwill | — | 0 | 0 | 0 | 0 | — |
| Total assets | 1,045 | 2,203 | 29,244 | 27,347 | 30,560 | 30,079 |
| Accounts payable | 63 | 43 | 2,803 | 2,585 | 5,543 | 5,664 |
| Total current liabilities | 1,051 | 91 | 6,931 | 5,552 | 6,315 | 6,444 |
| Lease liability, non-current | — | 0 | 642 | 539 | 745 | 597 |
| Total liabilities | 2,000 | 1,991 | 7,616 | 6,140 | 7,060 | 7,041 |
| Accumulated deficit | (20,219) | (32,655) | (59,400) | (63,906) | (69,040) | (75,015) |
| Total stockholders' equity | (955) | 212 | 21,628 | 21,207 | 23,501 | 23,038 |
| Total liabilities and equity | 1,045 | 2,203 | 29,244 | 27,347 | 30,560 | 30,079 |
| Common shares outstanding (cover page) thousands of shares | 465,006 | 7,130 | 22,586 | 99,453 | 2,708 | 4,906 |
- † Share count changed about 1/65 in the period ending 2021-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 1/37 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (SBFM's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | †Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | †Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | (2,784) | (12,436) | (26,744) | (4,506) | (5,134) | (5,975) |
| Stock-based compensation | 272 | — | — | — | — | — |
| Depreciation and amortization | — | — | — | 149 | 224 | 332 |
| Net cash from operating activities | (657) | (1,829) | (5,248) | (8,775) | (12,531) | (5,331) |
| Purchases of property and equipment | 1 | 0 | 194 | 82 | 1,657 | 174 |
| Net cash from investing activities | (1) | 0 | (14,619) | (656) | (2,321) | (836) |
| Proceeds from issuing common stock | — | 0 | 30,367 | 4,089 | 8,522 | 1,829 |
| Share repurchases | — | — | — | 541 | 3,140 | 0 |
| Net cash from financing activities | 1,608 | 2,905 | 39,465 | 3,426 | 9,290 | 4,748 |
- † Share count changed about 1/65 in the period ending 2021-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 1/37 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
- A cell reading “year only” links to a 10-K that gives only the full year: without all three earlier quarters there is no fourth quarter to work out, and the year total is never shown as a quarter.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Sunshine Biopharma | 13,748 | 9,264 | (918)* | 3.9M | 15.0 quarters | 10-QJun 30, 2026 |
| Neuphoria Therapeutics | 19,866 | year only | 1,214* | 5.4M | — | 10-KJun 30, 2026 |
| CV Sciences | 266 | 2,985 | 20* | 225.8M | — | 10-QJun 30, 2026 |
| Minerva Neurosciences | 24,652 | not reported | (13,345)* | 47.7M | 5.6 quarters | 10-QJun 30, 2026 |
| Zeo ScientifiX | 2,265 | not reported | not reported | 7.8M | — | 10-KTJun 30, 2026 |
| Bolt Biotherapeutics | 12,860 | 5 | (6,540)* | 1.9M | 2.7 quarters | 10-QJun 30, 2026 |
| Intensity Therapeutics | 9,529 | not reported | (2,340)* | 3.3M | 4.1 quarters | 10-QJun 30, 2026 |
| Genprex | 15,154 | not reported | (5,139)* | 819,709 | 2.9 quarters | 10-QJun 30, 2026 |
| Protagenic Therapeutics, Inc.\new | 566 | not reported | (944) | 1.8M | 0.6 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.